Approved for use through 9/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of \$2^2\$

d to respond to a collection of information un	tess it displays a valid OMB control number
Confirmation Number	3740
Application Number	10/690,115
Filing Date	10-21-2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Brenda Libby Coleman
Attomay Docket Number	PRD2033LISNP

## HE DATENT DOCUMENTS

Examiner Initials	Cite	U.S. Patent Doc.	ment			
		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages of relevant figures appear
/B.C./		5,756,504	Α	Bock et al.	05-26-1998	
/B.C./		5,889,006	А	Lowe et al.	03-30-1999	
/B.C./		6,596,706	B1	Kikuchi et al.	07-22-2003	Corresponding English equivalent to WO 9924475
			- 7			

## FOREIGN PATENT DOCUMENTS

		Foreign	Patent Docume	nt		Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup> Ki	ndCode <sup>5</sup>	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear	T <sup>6</sup>
/B.C./		wo	952544 3	A1	Merck & Co., Inc.	09-28-1995		
/B.C./		wo	962619 6	A2	Schering Corporation	09-29-1995		
/B.C./		wo	980529 2	A2	Schering Corporation	02-12-1998		
** /B.C./		wo	992447 5	A1	Dailchi Pharmaceutical Co., Ltd.	05-20-1999	See corresponding US Patent 6,596,706	

Signature Considered Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformal	
and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2	

Kinds Code of U.S. Patent Documents at <u>www.unipol.orgy</u>. Enter Office that assued the document, by the two letter Code (WIPO Sanindars S.S.), of or Japanese patent documents, the indication of the year of the region of the Emperor unall precede the serior all number of the particle counters, the disclaim of the Comment under WIPO Sanindar ST., 16 if possible. Applicated to place a crice from the region of the Emperor of t

England angingage literateation is enter-risk or proceedings of the confiction of the confiction of the process of the confiction of the process of the confiction of the conf

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (04-07) Approved for use through 9/30/2007. OMB 0651-0031

U.S. Patient and Trademark Officer U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 32

Confirmation Number	3740
Application Number	10/690,115
Filing Date	10-21-2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Brenda Libby Coleman
Attorney Docket Number	PRD2033LISNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's nitials*	Cite No.1	include name of the author (in CAPTIAL ETTERS), tide of the article (when appropriate), tide of the term (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/B.C./		IBRAHIM, EL SEBAI A. et al.: "Synthesis of 4-Substituted Aminobenzoate Quaternary Salts as Potent Antispasmodic Agents"; J. of Pharmaceutical Sciences (1979) 68(3): 332-335.	
* /B.C./		MIOCQUE, MARCEL et al.: "Derivatives of Imipramine: Aminomethylation of Diphenylamine and of Iminodibenzyl"; Eur. J. Med. Chem. – Chimica Therapeutica, (May-June 1977) 12(3): 219-225. Note: Copy of English-language translation is attached.	
	-		

Examiner Signature /Brenda Coleman/ Date O2/18/2008

structures only

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

i Applicant's unique cilation designation numbre (potional). Applicant is to place a check mark here I English language Translation is attached. This collection of information is required by 37 CFR 137 and 138. The information required to obtain or retain a benefit by the public which is its office (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including giarriering, propriang, and submitting the completed application to the USPTO. The rest Way depending upon the individual case. Any comments on the amount of time you are required to complete this should be sent to the Chief Information Officer, U.S. Patient in all Trademark AQDRESS. SERVI. (1) C. Commissioner for Patients. P.O. 80 et 459. Absorbation V.A. 2213-1439